|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル． モリソン，シェリー |
ドメイン‐変性不変部を有する抗体
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
DE69303494T2
(de)
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
EP0826696B1
(de)
|
1996-09-03 |
2002-05-29 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
|
|
CN1204147C
(zh)
|
1998-02-25 |
2005-06-01 |
利思进药品公司 |
提高以抗体为基础的融合蛋白的循环半衰期的方法
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
KR100508289B1
(ko)
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
PL195870B1
(pl)
|
1998-08-11 |
2007-11-30 |
Biogen Idec Inc |
Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
|
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
ATE311199T1
(de)
|
1999-05-07 |
2005-12-15 |
Genentech Inc |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
|
EP1274720A4
(en)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
FUSION PROTEINS CONTAINING ALBUMIN
|
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
|
AU2002250293B2
(en)
|
2001-03-09 |
2007-10-11 |
Arnason, Barry G. Mr |
Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
|
|
JP2005510470A
(ja)
|
2001-09-28 |
2005-04-21 |
エリューシス セラピューティクス，インコーポレーテッド |
二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
RU2004127458A
(ru)
|
2002-02-14 |
2005-10-27 |
Иммуномедикс, Инк. (Us) |
Анти-cd20 антитела, их гибридные белки и способы их использования
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
ES2559763T3
(es)
|
2002-09-10 |
2016-02-15 |
Affimed Gmbh |
Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
KR20110017020A
(ko)
|
2002-10-17 |
2011-02-18 |
젠맵 에이/에스 |
Ｃｄ20에 대한 인간 모노클로날 항체
|
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
KR101351122B1
(ko)
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Ｃｄ２０-특이적 항체 및 이를 이용한 방법
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
EP1629013B1
(en)
|
2003-05-31 |
2018-01-24 |
Amgen Research (Munich) GmbH |
Pharmaceutical composition comprising a bispecific antibody specific for epcam
|
|
DK1629011T3
(da)
|
2003-05-31 |
2010-05-03 |
Micromet Ag |
Humane anti-humane-DC3-bindingsmolekyler
|
|
US7700097B2
(en)
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
|
BRPI0412629A
(pt)
|
2003-08-29 |
2006-09-26 |
Genentech Inc |
método de tratamento de disfunção ocular em mamìferos
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
ZA200601699B
(en)
|
2003-10-16 |
2007-05-30 |
Micromet Ag |
Multispecific deimmunized CD3-binders
|
|
KR20060107555A
(ko)
|
2003-12-19 |
2006-10-13 |
제넨테크, 인크. |
이식 거부에서 ｃｄ20의 검출
|
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
EP1773393A2
(en)
|
2004-05-05 |
2007-04-18 |
Genentech, Inc. |
Preventing autoimmune disease by using an anti-cd20 antibody
|
|
MXPA06014075A
(es)
|
2004-06-03 |
2007-03-15 |
Novimmune Sa |
Anticuerpos anti-cd3 y metodos de uso de los mismos.
|
|
CA2568336A1
(en)
|
2004-06-04 |
2005-12-22 |
Genentech, Inc. |
Method for treating lupus
|
|
RU2411956C2
(ru)
|
2004-10-05 |
2011-02-20 |
Дженентек, Инк. |
Способ лечения васкулита
|
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
|
US20120189643A1
(en)
|
2004-11-30 |
2012-07-26 |
Carton Jill M |
Toll Like Receptor 3 Antagonists, Methods and Uses
|
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
WO2006116369A2
(en)
|
2005-04-22 |
2006-11-02 |
Genentech, Inc. |
Method for treating dementia or alzheimer's disease with a cd20 antibody
|
|
KR20080031001A
(ko)
|
2005-06-02 |
2008-04-07 |
아스트라제네카 아베 |
Ｃｄ20에 대한 항체 및 그의 용도
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
JP5364870B2
(ja)
|
2005-08-19 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
|
|
EP1943332A4
(en)
|
2005-10-14 |
2011-04-13 |
Medimmune Inc |
CELLULAR DISPLAY OF ANTIBODY LIBRARIES
|
|
US8075884B2
(en)
|
2006-01-12 |
2011-12-13 |
Alexion Pharmaceuticals, Inc. |
Antibodies to OX-2/CD200 and uses thereof
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
ES2965283T3
(es)
|
2006-03-15 |
2024-05-28 |
Alexion Pharma Inc |
Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
|
|
TW200808347A
(en)
|
2006-03-23 |
2008-02-16 |
Kirin Brewery |
Agonistic antibody directed against human thrombopoietin receptor
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
CN104497143B
(zh)
|
2007-03-29 |
2020-08-25 |
健玛保 |
双特异性抗体及其制造方法
|
|
US20100183615A1
(en)
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
SG10201808730VA
(en)
|
2007-04-03 |
2018-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific binding domain
|
|
EP2158318A2
(en)
|
2007-05-14 |
2010-03-03 |
Biogen Idec MA, Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
KR100897938B1
(ko)
|
2007-05-30 |
2009-05-18 |
주식회사 제넥신 |
면역글로불린 융합 단백질
|
|
EP2170951A2
(en)
|
2007-05-31 |
2010-04-07 |
Genmab A/S |
Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
|
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー／エス |
安定なＩｇＧ４抗体
|
|
WO2009006520A1
(en)
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
|
BRPI0813985B1
(pt)
|
2007-07-31 |
2022-05-10 |
Regeneron Pharmaceuticals, Inc |
Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
|
|
MY161564A
(en)
|
2007-08-10 |
2017-04-28 |
Regeneron Pharma |
High affinity human antibodies to human nerve growth factor
|
|
US20110243931A1
(en)
|
2007-09-02 |
2011-10-06 |
Thomas Friess |
Combination therapy with type i and type ii anti-cd20 antibodies
|
|
EP3415529B1
(en)
|
2007-09-26 |
2020-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
CN101939425B
(zh)
|
2007-09-26 |
2014-05-14 |
中外制药株式会社 |
抗il-6受体抗体
|
|
CN104193824A
(zh)
|
2008-02-20 |
2014-12-10 |
G2炎症私人有限公司 |
人源化抗-C5aR抗体
|
|
WO2009106096A1
(en)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Treatment of resistant tumors with trifunctional antibodies
|
|
WO2010054212A1
(en)
|
2008-11-06 |
2010-05-14 |
Alexion Pharmaceuticals, Inc. |
Engineered antibodies with reduced immunogenicity and methods of making
|
|
CN106390114A
(zh)
|
2008-11-07 |
2017-02-15 |
安进研发（慕尼黑）股份有限公司 |
小儿急性淋巴细胞白血病的治疗方法
|
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
|
CA2745439C
(en)
|
2008-12-03 |
2019-10-15 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
BRPI1006998A2
(pt)
|
2009-01-23 |
2015-08-25 |
Biogen Idec Inc |
Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
|
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
LT2975051T
(lt)
|
2009-06-26 |
2021-07-12 |
Regeneron Pharmaceuticals, Inc. |
Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
SI2506871T1
(sl)
|
2009-11-30 |
2016-12-30 |
Janssen Biotech, Inc. |
Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
HRP20151188T4
(hr)
|
2010-02-08 |
2021-10-01 |
Regeneron Pharmaceuticals, Inc. |
Miš sa zajedničkim lakim lancem
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
EP2563812A4
(en)
|
2010-04-30 |
2016-01-13 |
Alexion Pharma Inc |
ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS
|
|
EP2585828A4
(en)
*
|
2010-06-25 |
2014-03-12 |
Glaxo Group Ltd |
METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
CN103249742B
(zh)
|
2010-09-16 |
2017-04-12 |
巴利奥医药股份公司 |
抗人肿瘤坏死因子1型受体抗体
|
|
TWI638833B
(zh)
|
2010-11-30 |
2018-10-21 |
中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
CA2822366A1
(en)
|
2010-12-23 |
2012-06-28 |
Janssen Biotech, Inc. |
Active protease-resistant antibody fc mutants
|
|
BR112013020086B1
(pt)
|
2011-02-08 |
2020-12-08 |
Medimmune, Llc |
Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
US9587021B2
(en)
|
2011-05-21 |
2017-03-07 |
Macrogenics, Inc. |
CD3-binding molecules capable of binding to human and non-human CD3
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20140370012A1
(en)
|
2012-01-27 |
2014-12-18 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
|
WO2013157105A1
(ja)
|
2012-04-18 |
2013-10-24 |
公立大学法人大阪市立大学 |
ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
|
|
KR20150023535A
(ko)
|
2012-06-05 |
2015-03-05 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
|
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
PL2900694T3
(pl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Dwuswoiste przeciwciała igg jako aktywatory komórek t
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
KR102363220B1
(ko)
|
2013-07-05 |
2022-02-15 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
|
CN105531374A
(zh)
|
2013-07-12 |
2016-04-27 |
酵活有限公司 |
双特异性cd3和cd19抗原结合构建体
|
|
MX379030B
(es)
|
2013-12-17 |
2025-03-10 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
CA2925677A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR102777500B1
(ko)
|
2015-09-23 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
최적화된 항-cd3 이중특이적 항체 및 이의 용도
|
|
HUE063377T2
(hu)
*
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
US20170174781A1
(en)
|
2015-12-22 |
2017-06-22 |
Regeneron Pharmaceuticals, Inc. |
Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
|
|
EP3252078A1
(en)
*
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
MA46417A
(fr)
|
2016-09-23 |
2019-07-31 |
Regeneron Pharma |
Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
|
|
US10738130B2
(en)
|
2016-09-23 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
|
|
KR20190074300A
(ko)
*
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
MX2019006954A
(es)
*
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
PT3844189T
(pt)
*
|
2018-08-31 |
2025-01-29 |
Regeneron Pharma |
Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
|
|
CA3148849A1
(en)
|
2019-07-26 |
2021-02-04 |
Velo3D, Inc. |
Quality assurance in formation of three-dimensional objects
|